INTRODUCTION {#s1}
============

Long noncoding RNAs (lncRNAs) are the RNA molecules with size exceeding 200 nts and apparently lack of protein-coding capacity \[[@R1]\]. Nevertheless, lncRNAs have been found being involved in almost all aspects of gene expression through interactions with other components such as proteins, RNAs and DNAs \[[@R2], [@R3]\]. Increasing evidence suggests lncRNAs could be the key regulators of different cellular processes. Moreover, the dysregulation of homeostatic control of lncRNAs biogenesis could be associated with multiple pathological cancers \[[@R4], [@R5]\]. The regulating lncRNAs have been shown aberrant expression in tumor tissues and participate in the onset of cancer \[[@R6]--[@R8]\]. Because of involvement in many cellular caner pathways, abundant lncRNAs were identified by high-throughput RNA sequencing (RNA-Seq), especially in data of the Cancer Genome Atlas (TCGA) project \[[@R5], [@R9]\], and expected to play crucial role in cancer diagnosis, detection and therapy.

Recently, a long intergenic noncoding RNA PVT1, homologous to the mouse plasmacytoma variant translocation gene (Pvt1), has attracted widespread attention. The lncRNA PVT1 lies in human chromosome 8q24.21, which is a recognized cancer risk locus with the top target of copy number alterations \[[@R10]\], and has been reported to be dysregulated in various human tumors, such as gastric cancer, non-small cell lung cancer, colorectal cancer, esophageal cancer, pancreatic cancer, hepatocellular carcinoma \[[@R5], [@R11], [@R12]\]. Abnormal expression of PVT1 in cancerous tissue has confirmed it as an important player in tumorigenesis of cancers \[[@R10], [@R13]\]. Furthermore, high expression of PVT1 was identified being associated with poor prognosis of patients \[[@R14]--[@R17]\]. More importantly, PVT1 could be steadily detected in patient's body fluid including blood and saliva, and might be a noninvasive biomarker for cancer diagnosis and detection \[[@R18]--[@R22]\]. However, the diagnosis effect of PVT1 is not clear in most cancers, while the expression of PVT1 has been tested in 33 type cancers of TCGA database \[[@R12]\]. Moreover, the reported effect of PVT1 on diagnosis and detection is controversial, and no meta-anlysis has investigated the relationship between PVT1 epression and cancer diagnosis and detection.

The present study aimed to analyze the differential expression of PVT1 between types of cancer and corresponding normal tissue, explore the effect of PVT1 on cancer diagnosis with TCGA data, and further pool the cancer diagnosis and detection effect of PVT1 by meta-analysis.

RESULTS {#s2}
=======

The expression of PVT1 in TCGA cancers {#s2_1}
--------------------------------------

The expression of PVT1 was checked in TCGA database by firebrowse (<http://firebrowse.org/>), and PVT1 was stably detected in 32 types of cancer as well as 22 types of corresponding normal tissue (Figure [1](#F1){ref-type="fig"}). Because of PVT1 detected in only two normal tissues of thymoma patients, PVT1 sequencing data of 21 types were chose to analyze the differential expression between cancers and corresponding normal tissues. The PVT1 expression was significantly upregulated in 18 types of cancers; although, the PVT1 expression of thyroid carcinoma was significantly lower than that of normal tissues (Table [1](#T1){ref-type="table"}).

![PVT1 differential plot for 32 types of cancers in TCGA database](oncotarget-08-75455-g001){#F1}

###### The differentiation and diagnosis value of PVT1 expression in cancers and corresponding normal ones of TCGA database

  Type of cancer   Type of tissue   NO. of Samples   Mann-Whitney U test   Diagnosis tese                                  
  ---------------- ---------------- ---------------- --------------------- ---------------- ---------------------- ------- -------
  BLCA             cancer           407              −4.502                \< 0.0001        0.805 (0.718--0.893)   0.801   0.737
                   normal           19                                                                                     
  BRCA             cancer           1097             −9.564                \< 0.0001        0.785 (0.723--0.806)   0.734   0.663
                   normal           121                                                                                    
  CESC             cancer           303              −2.099                0.036            0.774 (0.540--1.000)   0.828   0.800
                   normal           5                                                                                      
  CHOL             cancer           36               −4.313                \< 0.0001        0.969 (0.915--1.000)   0.972   0.889
                   normal           9                                                                                      
  COAD             cancer           286              −93789                \< 0.0001        0.963 (0.921--1.000)   0.976   0.953
                   normal           43                                                                                     
  ESCA             cancer           184              −5.116                \< 0.0001        0.941 (0.879--1.000)   0.859   0.833
                   normal           12                                                                                     
  GBM              cancer           154              −3.257                0.001            0.735 (0.602--0.868)   0.708   0.722
                   normal           18                                                                                     
  HNSC             cancer           520              −3.204                0.001            0.642 (0.571--0.714)   0.675   0.619
                   normal           46                                                                                     
  KIRC             cancer           533              −13.540               \< 0.0001        0.988 (0.978--0.998)   0.974   0.959
                   normal           73                                                                                     
  KICH             cancer           66               −2.321                0.020            0.658 (0.547--0.769)   0.652   0.720
                   normal           25                                                                                     
  KIRP             cancer           290              −8.331                \< 0.0001        0.943 (0.910--0.976)   0.886   0.909
                   normal           33                                                                                     
  LIHC             cancer           371              −8.619                \< 0.0001        0.869 (0.832--0.905)   0.819   0.808
                   normal           52                                                                                     
  LUAD             cancer           515              −11.202               \< 0.0001        0.938 (0.899--0.978)   0.899   0.885
                   normal           61                                                                                     
  LUSC             cancer           502              −10.922               \< 0.0001        0.964 (0.947--0.981)   0.924   0.902
                   normal           51                                                                                     
  PAAD             cancer           178              −0.847                0.397            0.611 (0.324--0.899)   0.775   0.600
                   normal           5                                                                                      
  PRAD             cancer           497              −8.486                \< 0.0001        0.854 (0.808--0.900)   0.801   0.755
                   normal           53                                                                                     
  READ             cancer           94               −5.253                \< 0.0001        0.985 (0.957--1.000)   0.989   0.909
                   normal           11                                                                                     
  SARC             cancer           259              −0.550                0.583            0.566 (0.333--0.798)   0.598   0.667
                   normal           6                                                                                      
  STAD             cancer           415              −7.541                \< 0.0001        0.884 (0.837--0.930)   0.824   0.800
                   normal           35                                                                                     
  THCA             cancer           505              −4.589                \< 0.0001        0.328 (0.269--0.386)   0.349   0.448
                   normal           67                                                                                     
  UCEC             cancer           176              −1.922                0.055            0.619 (0.510--0.727)   0.574   0.600
                   normal           25                                                                                     

Abbreviations: BLCA, bladder cancer; BRCA, breast cancer; CESC, cervical cancer; CHOL, bile duct cancer; COAD, colon cancer; ESCA, esophageal cancer; GBM, glioblastoma; HNSC, head and neck cancer; KIRC, kidney clear cell carcinoma; KICH, kidney chromophobe; KIRP, kidney papillary cell carcinoma; LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic cancer; PRAD, prostate cancer; READ, rectal cancer; SARC, sarcoma; STAD, stomach cancer; THCA, thyroid cancer.

Diagnosis value of PVT1 in TCGA cancers {#s2_2}
---------------------------------------

Receiver operating characteristic (ROC) curve was further used to analyze the diagnostic effect of PVT1 in the 21 type cancers. As shown in Table [1](#T1){ref-type="table"}, the values of area under receiver operating characteristic curve (AUC) were more than 0.50 in 16 of them, which were 0.805 (*P* \< 0.0001), 0.785 (*P* \< 0.0001), 0.774 (*P* = 0.036), 0.969 (*P* \< 0.0001), 0.963 (*P* \< 0.0001), 0.941 (*P* \< 0.0001), 0.735 (*P* = 0.001), 0.642 (*P* = 0.001), 0.988 (*P* \< 0.0001), 0.658 (*P* = 0.020), 0.943 (*P* \< 0.0001), 0.869 (*P* \< 0.0001), 0.938 (*P* \< 0.0001), 0.964 (*P* \< 0.0001), 0.854 (*P* \< 0.0001), 0.985 (*P* \< 0.0001, 0.884 (*P* \< 0.0001), for bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical cancer (CESC), bile duct cancer (CHOL), colon cancer (COAD), esophageal cancer (ESCA), glioblastoma (GBM), head and neck cancer (HNSC), kidney clear cell carcinoma (KIRC), kidney chromophobe (KICH), kidney papillary cell carcinoma (KIRP), liver cancer (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate cancer (PRAD), rectal cancer (READ), and stomach cancer (STAD). Because of the tissues derived from different organs, the diagnostic effects of PVT1 were also tested in the same organ cancers. PVT1 was a reliable diagnosis biomarkers for lung cancer, hepatobiliary cancer, renal tumor, colorectal carcinoma with the AUCs being 0.946 (0.924--0.969), 0.881 (0.849--0.913), 0.952 (0.938--0.967), 0.968 (0.934--0.999), respectively (Table [2](#T2){ref-type="table"}).

###### The differentiation and diagnosis value of PVT1 expression in cancers from different organs and corresponding normal ones of TCGA database

  Series of Cancers      Type of tissue   NO. of Samples   Mann-Whitney *U* test   Diagnosis tese                                  
  ---------------------- ---------------- ---------------- ----------------------- ---------------- ---------------------- ------- -------
  lung cancer            cancer           1017             25.29                   \< 0.0001        0.946 (0.924--0.969)   0.895   0.902
  normal                 112                                                                                                       
  Uterine cancer         cancer           479              3.073                   0.002            0.683 (0.588--0.777)   0.662   0.633
  normal                 30                                                                                                        
  Hepatobiliary Cancer   cancer           407              14.91                   \< 0.0001        0.881 (0.849--0.913)   0.83    0.82
  normal                 61                                                                                                        
  Renal tumor            cancer           889              34.46                   \< 0.0001        0.952 (0.938--0.967)   0.909   0.916
  normal                 131                                                                                                       
  Colorectal carcinoma   cancer           380              21.362                  \< 0.0001        0.968 (0.934--0.999)   0.979   0.944
  normal                 54                                                                                                        

Studies searching for PVT1 expression on the cancer diagnosis/ detection and quality assessment of diagnosis tests {#s2_3}
------------------------------------------------------------------------------------------------------------------

The literature search resulted in 6 studies eligible for the meta-analysis ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), and all were from China \[[@R11], [@R18]--[@R21], [@R23]\]. The studies involved 439 cancer patients and 434 controls, with mean sample size of 73.2 patients (range 20 to 111). Five different types of cancer were evaluated: gastric cancer (*n* = 2), clear cell renal cell carcinoma, melanoma, cervical cancer, and Non-small cell lung cancer (*n* = 1 each). The level of PVT1 was detected in patient's tumor tissue or circulating blood by RT-PCR; and the negative control was adjacent noncancerous tissue or healthy serum. The main characteristics of each study are summarized in Table [3](#T3){ref-type="table"}.

###### Basic data for all included studies in the meta-analysis

  Author           Year                   Specimen   Derived                                                                                           Cancer type                               Diagnosis/detection tests                                  
  ---------------- ---------------------- ---------- ------------------------------------------------------------------------------------------------- ----------------------------------------- --------------------------- ---------------------- ------- -------
  Wu Y, et al.     2016                   blood      Fudan University Shanghai Cancer Center, China                                                    clear cell renal cell carcinoma (ccRCC)   24/27                       0.733 (0.582--0.884)   0.700   0.732
  37/35            0.682 (0.535--0.829)   0.644      0.624                                                                                                                                                                                                  
  Chen X, et al.   2017                   blood      The253rd Hospital of PLA (Hohhot, Inner Mongolia, China).                                         Melanoma                                  51/47                       0.939 (0.890--0.987)   0.941   0.851
  Yang J, et al.   2016                   blood      The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine                     Cervical cancer(CC)                       88/86                       0.892 (0.838--0.946)   0.867   0.733
  Gao J, et al.    2015                   blood      Linyi People Hospital Hospital, Shandong Province, China                                          Gastric cancer(GC)                        20/20                       0.797 (0.731--0.863)   0.708   0.913
  Yuan C, et al.   2015                   Tissue     The First Affiliated Hospital of Nanjing Medical University and Yangzhou No.1 People's hospital   Gastric cancer (GC)                       111/111                     0.728 (0.665--0.786)   0.802   0.604
  Cui D, et al.    2015                   Tissue     The First Affiliated Hospital of Nanjing Medical University                                       Non-small cell lung cancer (NSCLC).       108/108                     0.736 (0.673--0.799)   0.815   0.617

Six published studies and 21 TCGA based diagnosis tests, with 8877 cases and 1290 controls, were enrolled. Each of them presented the AUC, sensitivity and specificity. In addition, the participants of a study were divided into two groups for testing and validation. Consequently, we assessed the overview quality of 28 diagnosis tests and reported them in [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}. The risk of bias in patient selection was high in 28 tests (100%), mainly due to the 2-gate design (case-control) in the majority of tests. Because different test thresholds were selected to optimize sensitivity and specificity, the risk of bias of index test performance was high in 28 tests (100%). As some samples were deleted for the PVT1 expression undetected, the risk of bias arising from patient flow and timing of procedures was also considered high in the majority of studies (*n* = 23, 82%). However, the risk of bias for reference standard definition was low in the majority of studies (*n* = 28; 100%). Furthermore, for the regarding applicability, there was unclear risk identified for patient selection (*n* = 21, 75%), reference standard (*n* = 21, 75%), and low risk for reference standard (n = 28, 100%).

Pooled effect of PVT1 on cancer diagnosis in tissue {#s2_4}
---------------------------------------------------

According to the criteria of diagnosis tests performed in tissue, 2 published studies \[[@R11], [@R23]\] and 21 TCGA based diagnosis tests, with 8657 cancer tissues and 1075 corresponding normal ones, were chose. Because of severe heterogeneity resulting from severe threshold effect (spearman coefficient = −0.889, *P*~Q~ \<0.0001) among 23 diagnosis tests (I^2^ = 97.4%, *P*~Q~ \< 0.0001), the random-effects model was used to calculate the pooled effect. As shown in Figure [2](#F2){ref-type="fig"}, the pooled AUC was 0.81 (95% CI: 0.76--0.86). Furthermore, the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odd ratio (DOR) was conducted with the values being 0.83 (95% CI: 0.76--0.89), 0.74 (95% CI: 0.70--0.84), 3.77 (95% CI: 2.56--5.54), 0.21 (95% CI: 0.14--0.34), 17.25 (95% CI: 8.43--35.27), respectively ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). The Fagan plot and the summary operating characteristic curve (sROC) with AUC of 0.87 (95%CI: 0.84--0.90) were shown in Figure [3](#F3){ref-type="fig"} and Figure [4](#F4){ref-type="fig"}; which suggested that the diagnostic accuracy of tissue PVT1 for cancers was relatively high.

![Pooled AUC of PVT1 for cancer diagnosis / detection in tissue\
Abbreviations: AUC, area under receiver operating characteristic curve; SE, standard error; IV, inverse variance methods; CI, confidence interval.](oncotarget-08-75455-g002){#F2}

![Fagan diagram evaluating the overall diagnostic value of PVT1 in tissue](oncotarget-08-75455-g003){#F3}

![The SROC curve of PVT1 for the diagnosis of various cancers in tissue](oncotarget-08-75455-g004){#F4}

Pooled diagnostic values of circulating PVT1 {#s2_5}
--------------------------------------------

Four studies with 220 patients and 215 health controls showed data for circulating PVT1 on cancer detection/diagnosis. The pooled AUC was 0.83 (95%CI: 0.75--0.91) for 5 tests under the random-effects model (I^2^=82.1%, *P*~Q~ \< 0.0001) ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). With no significant threshold effect (spearman coefficient = -0.300, P~Q~ = 0.624), the pooled sensitivity, specificity, PLR, NLR, DOR were calculated to be 0.81 (95% CI: 0.76--0.86), 0.76 (95% CI: 0.70--0.81), 3.28 (95% CI: 2.05--5.25), 0.27 (95% CI: 0.14--0.51), 13.86 (95% CI: 4.70--40.66), respectively ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). Moreover, the area under sROC was 0.85 (95%CI: 0.79--0.91). The diagnostic accuracy of circulating PVT1 on cancers was also relatively high with the Fagan plot and sROC curve present in Figure [5](#F5){ref-type="fig"} and Figure [6](#F6){ref-type="fig"}.

![Fagan diagram evaluating the overall diagnostic value of circulating PVT1](oncotarget-08-75455-g005){#F5}

![The SROC curve of circulating PVT1 for the diagnosis of various cancers](oncotarget-08-75455-g006){#F6}

Sensitivity analysis {#s2_6}
--------------------

Sensitivity analysis was conducted for the association between cancer diagnosis/detection and PVT1 expression in tissues as well as in serum. Each diagnosis test was deleted in turn to examine the influence of the removed data on the overall AUC. The pooled AUC values of PVT1in tissue and serum remained above 0.50 throughout (data not shown), while the summary sensitivity and specificity, PLR, NLR, and area under sROC were altered (data not shown).

Publication bias {#s2_7}
----------------

Due to PVT1 expression acting as a diagnostic biomarker of cancer \[[@R24], [@R25]\], publication bias of test accuracy was checked by a Deek's funnel plot (Figure [7](#F7){ref-type="fig"}), which showed that no significant bias existed in tissue (*t* = 0.39, *P* = 0.704) and serum (*t* = −0.47, *P* = 0.673).

![Deek's funnel plot to evaluate the publication bias of test accuracy](oncotarget-08-75455-g007){#F7}

DISCUSSION {#s3}
==========

This current study aimed to analyze the differential expression of PVT1 in different types of common cancers and assess the effect of PVT1 expression on cancer diagnosis/detection. Basing on TCGA RNA-Seq data, the expression of PVT1 was suggested being a possible biomarker to distinguish cancer from normal tissue. The pooled effect showed that diagnostic accuracy of PVT1 for cancers was relatively high in tissue and serum. PVT1 might act as an effective biomarker for cancer diagnosis/detection.

With the advance on RNA-Seq technique and improvement of bioinformatics, numerous lncRNAs were detected and the representative RNA sequencing data of cancer was stored in TCGA database \[[@R26], [@R27]\], which provided more clues for cancer detection and therapy. However, only a few lncRNAs had been further explored to fully understand the role in development, diagnosis, and therapy of cancers. PVT1, a novel lncRNA initially found being co-expression with MYC, was confirmed that could promote the stability of MYC protein which participated in oncogene activation through Akt/c-Myc signaling pathway \[[@R10], [@R11], [@R28], [@R29]\]. In TCGA database, PVT1 could be detected in all included cancers. Our reanalysis of RNA-Seq data showed that PVT1 significantly upregulated in 18 types of cancerous tissues, as 16 could be accurately differentiated from corresponding normal tissue in the diagnosis tests. Furthermore, research in the mechanism found PVT1 could target genes such as LASP1 \[[@R34]\], FOXM1 \[[@R31]\], RSPO1 \[[@R32]\], p15, p16 \[[@R33]\], EZH2, TSHR \[[@R33]\], and NOP2 \[[@R35]\] to promote tumor cell proliferation, migration and invasive capability *in vitro*. Moreover, PVT1 could also contribute to the epithelial-to-mesenchymal transition (EMT), which was required for cancer metastasis and invasion \[[@R16], [@R36], [@R37]\]. Therefore, PVT1 is a common oncogenic lncRNA participating in tumor development and could be used as a biomarker for cancer detection / diagnosis.

In the present meta-analysis, the pooled-AUC of 0.81 (95% CI: 0.76--0.86) and the DOR of 17.25 (95% CI: 8.43--35.27) in tissues showed that the PVT1 had relatively high efficiency to distinguish cancer; although, the pooled sensitivity and specificity were not convincing for the significant threshold effect existing \[[@R38], [@R39]\]. Similar to the performance in tissues, the pooled--AUC of circulating PVT1 was still more than 0.80 with DOR being 13.86, which indicated that it was feasible to detect cancer by usingcirculating PVT1 \[[@R40], [@R41]\]. Meanwhile, the sensitivity of 0.83 (95% CI: 0.76--0.89) and the specificity of 0.74 (95% CI: 0.70--0.84) approved circulating PVT1 had a relatively high accuracy in human cancer detection. In addition, the Fagan's nomogram showed circulating PVT1 could raise the probability of cancer detection by 25.1% (pos*t*-test probability 45.1% - pre-test probability 20%) \[[@R42]\], which was similar to effect practiced in tissue. The pooled diagnostic values of circulating PVT1, like H19 \[[@R43]\], HULC \[[@R44]\], miR-31 \[[@R30]\], was higher than that of traditional clinical markers such as CEA and CA19--9. It all suggested that PVT1 expression, especially in serum, was a higher effective biomarker for human cancer detection.

Some meta-analyses focused on the association of lncRNAs such as BANCR \[[@R45]\], HOTTIP \[[@R46]\], CCAT2 \[[@R47]\], and metastasis as well as prognosis of cancers; all of them were based on the lncRNAs detected in tissues. To search for an applicable diagnosis biomarker, we focused on the effect of PVT1 expression, especially in serum, on diagnosis / detection. To our best knowledge, this is the first meta-analysis of PVT1 expression on cancer detection with the data from TCGA and published studies.

Our study contains some limitations. First, the samples of controls were few and publication bias existed. Second, because of severe threshold effect in TCGA data based analysis; the diagnostic accuracy of PVT1 could not be accurately confirmed in tissue. Third, because of the nature of the meta-analysis using aggregated group data, the confounding factors could not be controlled. Fourth, there were few studies on association of serum PVT1 expression with cancer diagnosis / detection, some of our significant findings was limited by the low precision as indicated by the wide confidence intervals. Therefore, studies with larger-scale, multicenter, high-quality and referring to multi-type cancer are needed to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

TCGA sequencing data {#s4_1}
--------------------

PVT1 RNA sequencing datasets of different cancers and corresponding normal tissues were downloaded from <https://xenabrowser.net/heatmap/> (TCGA database) with the format being Illumina Hiseq Pancan normalized, when the relative clinical data was from <https://portal.gdc.cancer.gov/projects/>(TCGA database).

Literature search strategy {#s4_2}
--------------------------

Reports of studies in English or Chinese language on the role of PVT1 in human cancer were searched in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases with the keywords "PVT1 and (cancer or tumor or neoplasm)". References of retrieved papers and conference reports were also searched to identify relevant studies. The last searching date was May 8, 2017.

Selection criteria of reported research {#s4_3}
---------------------------------------

The titles and abstracts of searched articles were checked by 3 authors (YZ, TW, ZS) after duplicates removed. Then, the full text of eligible articles was retrieved. Eligible articles should have the following criteria: 1) the expression of PVT1 was analyzed by detection/diagnosis of human cancer, 2) the expression of PVT1 was tested in cancer tissue or circulating blood by RT-PCR, fluorescence *in-situ* hybridization or RNA-Seq, and 3) diagnostic test indexes for detection/diagnosis (sensitivity, specificity, and AUC) were provided or could be calculated from the available data. Studies not fulfilling the criteria, reviews, animal/cell-line studies, and case reports were excluded. Furthermore, if more than 1 report from the same cohort was published, only the most recent publication was included. Consensus in searching and exclusion was resolved by discussion and with other 2 investigators (XC, DH) if needed.

Data extraction and quality assessment {#s4_4}
--------------------------------------

Two authors (YL, PL) extracted the following data by using an extraction form: first author's name, published year, region of cohort, sample size, cancer type, method to test PVT1, AUC, sensitivity, and specificity. The quality of diagnostic test studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS2).

Statistical methods {#s4_5}
-------------------

Mann-Whitney *U* test was applied to analyze the differential expression of PVT1between cancerous tissues and corresponding normal ones. ROC curve was performed to assess the effect of PVT1 expression in cancer diagnosis/detection. In the meta-analysis, the heterogeneity among studies was tested by Inconsistency (I^2^) and Q tests (chi-square test). If no statistical heterogeneity was found (I^2^ \< 50%, *P*~Q~ \> 0.05), a fixed-effects model was used to estimate the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odd ratio (DOR), and summary operating characteristic curve (sROC). Otherwise, a random-effects model was used. Moreover, Deek's tests were used to assess publication bias. In addition, Engauge Digitizer 4.1 and Origin 8 were used to analyze AUC, when AUC and 95% CIs were not provided directly in some studies. All tests, being considered statistically significant with *P* \< 0.05, were two sided and performed by STATA 14.0, Meta-DiSc 1.4, and Review Manager 5.3 (Cochrane network).

CONCLUSIONS {#s5}
===========

This meta-analysis is the first to demonstrate that high expression of the long noncoding RNA PVT1 is related to cancer detection. The expression of PVT1, especially tested in serum, might be a biomarker for cancer diagnosis / detection.
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